ALK and neoplasm: The current mandatory biomarkers to look for in late-stage NS-NSCLC include different genomic alterations present on EGFR, ALK, ROS1, NTRK, BRAF, MET, and RET, as well as the PD-L1 expression of tumor cells [4,5].